Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 11/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 11/20 | 0.35 |
| ▸ | NQO2 | P16083 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23208944 | 1.00 | MTNR1A (0.35) | MTNR1AMTNR1BNQO2CYP1A2KMT2A | |
| SCHEMBL3142042 | 0.79 | NQO2 (0.38) | MTNR1AMTNR1BNQO2CYP1A2KMT2A | |
| SCHEMBL1712251 | 0.77 | ERN1 (0.46) | MTNR1AMTNR1BHTR2CPOLBTDP1 | |
| SCHEMBL16511925 | 0.77 | MTNR1A (0.44) | MTNR1AMTNR1BCYP1A2KMT2AHTR2C | |
| SCHEMBL30492604 | 0.77 | MTNR1A (0.44) | MTNR1AMTNR1BCYP1A2KMT2AHTR2C | |
| SCHEMBL15512652 | 0.76 | HTT (0.37) | NQO2CYP1A2KMT2AALDH1A1HTT | |
| SCHEMBL14905348 | 0.76 | EGFR (0.41) | NQO2PTPN11EGFR | |
| SCHEMBL21631626 | 0.76 | PTPN11 (0.39) | NQO2PTPN11HTTEGFR | |
| SCHEMBL29971220 | 0.76 | PTPN11 (0.39) | NQO2PTPN11HTTEGFR | |
| SCHEMBL1222885 | 0.76 | BACE1 (0.53) | MTNR1AMTNR1BNQO2HTTEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11466016-B2 | Pharmaceutical compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11466016-B2 | Pharmaceutical compounds | MAPT, CYP3A5, SLC5A1 | MTNR1A 1850/4885MTNR1B 1856/4885NQO2 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.